Farmaco
ActiveThe computed 12-month bankruptcy probability of Farmaco is 1.7% (moderate). The 2025 annual accounts show equity of €1k and a net result of €15k. The figures fluctuate too strongly year-on-year for a reliable trend projection. Its solvency ranks better than 26% of 18040 sector peers (fiscal year 2025). The company has been active since 2020 and the Belgian State Gazette contains no insolvency or warning signals.
Checked score
Score 2025
54
/ 100
Fair
The score weighs solvency, liquidity, profitability and financial development. Bankruptcy probability contributes 35%. Every signal that weighs is under Signals.
Axes · tick = 2024
Profitability100▲+50
Solvency31▲+3
Growth58▲+26
Track record100
Bankruptcy probability, 12 months
1.7%
Moderate
0%0.5%1.5%4%10%≥ 25%
Credit advice for your own amount and term
Signals
Six signals. The signal on the left, the evidence on the right.
−lowers risk+raises risk○neutral
raises risk · Limited track record
This company has not been active as long as an established one and statistically fails somewhat more often.
KBO · incorporation dateAge against the risk zone
raises risk · Higher-failure-rate sector
In this sector companies fail more often than the Belgian average.
Gazette · bankruptcies per sector, NACE 47
Relative position
BE, all sectors
reference
Sector 47
higher
← fewer bankruptcies
more bankruptcies →
lowers risk · Growing equity
Reported equity is higher than in 2023 and did not fall compared with 2024. These amounts do not establish the cause of the change.
NBB · annual accounts 2025Equity per financial year
202122232425
2020 to 2025 · latest year €1k
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 10-02-2026, 171 days ahead of the deadline.
NBB · 6 filingsDeviation from the deadline
2025
171 d early
2024
13 d late
2023
27 d late
2022
28 d late
2021
19 d late
2020
25 d late
← before the deadline
after the deadline →
neutral · The next deadline is still running
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today.
Companies Code · seven monthsPosition in the running window
17-09-2026 today31-12-2026 close31-07-2027 deadline
Financials · fiscal year 2025, micro schema
Equity
€1k▲ 626%
2024 · €138
2020: €6k
2021: €11k
2022: €6k
2023: €874
2024: €138
2020 → 2025
Total assets
€17k▲ 252%
2024 · €5k
2020: €31k
2021: €34k
2022: €22k
2023: €9k
2024: €5k
2020 → 2025
Net result
€15k
2024 · €-737
2020: €6k
2021: €7k
2022: €190
2023: €-3k
2024: €-737
2020 → 2025
Working capital
€470
2024 · €-1k
2020: €-15k
2021: €-4k
2022: €-5k
2023: €-4k
2024: €-1k
2020 → 2025
Multi-year overview
Every figure with its change against the year before
▲ rise
▼ fall
Line20212022202320242025Trend
Equity€11k-€6k▼ 44.4%€874▼ 85.5%€138▼ 84.2%€1k▲ 626%
Operating result€10k-€2k▼ 82.9%€-2k€552€21k▲ 3,693%
Net result€7k-€190▼ 97.2%€-3k€-737▲ 76.6%€15k
Turnover and EBIT margin not published: the micro schema does not require them.
Result per fiscal year
Operating resultNet result
After the dip in 2023 the operating result has climbed two years in a row; 2025 is 3,693% above 2024 and is the highest result in the available series.
Balance-sheet composition
2025 in colour, 2024 as the grey bar beneath
Assets €17k
Fixed assets
€814▼ 43.9%
Current assets
€17k▲ 375%
Equity and liabilities €17k
Equity
€1k▲ 626%
Debt
€16k▲ 241%
The debt ratio falls from 97.2% to 94.2%. Equity and debt are higher.
Key figures and ratios
EBITDA
€22k▲
2024 · €5k
Cash flow
€15k▲
2024 · €4k
Solvency
5.8%
Current ratio
1.03
Quick ratio
1.03
Debt / equity
16.32
ROA
85.0%
Interest coverage
18.22▼
2024 · 87.56
Debt
€16k▲
2024 · €5k
Debt ≤ 1 year
€16k▲
2024 · €5k
Income taxes
€5k▲
2024 · €1k
A ratio outside any meaningful range has been withheld (balance sheet total €17k, equity €1k).
Green means a favourable move, even when the figure itself falls: as with debt or debt / equity.
Filed annual accounts
As filed with the NBB · 2025 against 2024
Balance sheet
Code20242025
Assets
Total assets20/58€5k€17k▲
Fixed assets21/28€1k€814▼
Tangible fixed assets22/27€1k€814▼
Plant, machinery and equipment23€604€318▼
Furniture and vehicles24€848€496▼
Current assets29/58€3k€17k▲
Amounts receivable within one year40/41€1k€15k▲
Trade receivables40€953€5k▲
Other amounts receivable41€427€10k▲
Cash at bank and in hand54/58€1k€1k▲
Deferred charges and accrued income490/1€1k€150▼
Equity and liabilities
Total equity and liabilities10/49€5k€17k▲
Equity10/15€138€1k▲
Contributions10/11€1k€1k=
Profit (loss) carried forward14€-862€0▲
Amounts payable17/49€5k€16k▲
Amounts payable within one year42/48€5k€16k▲
Trade debts44€737€330▼
Suppliers440/4€737€330▼
Taxes, remuneration and social security45€423€2k▲
Taxes450/3€423€2k▲
Other amounts payable47/48€4k€14k▲
Accrued charges and deferred income492/3€26€284▲
Income statement
Code20242025
Non-recurring operating income76A-€6k
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€4k€638▼
Other operating charges640/8€521€567▲
Gross operating margin9900€5k€22k▲
Operating profit (loss)9901€552€21k▲
Financial income75/76B-€221
Recurring financial income75-€221
Financial charges65/66B€55€1k▲
Recurring financial charges65€55€1k▲
Profit (loss) for the period before taxes9903€497€20k▲
Income taxes67/77€1k€5k▲
Profit (loss) for the period9904€-737€15k▲
Profit (loss) for the period to be appropriated9905€-737€15k▲
Appropriation of the result
Profit (loss) to be appropriated9906€-862€14k▲
Profit (loss) brought forward from the previous period14P€-126€-862▼
Transfer from equity791/2€0-
Profit to be distributed694/7€0€14k▲
Return on contributions (dividend)694€0€14k▲
The notes to these accounts (8 items: statements of assets and debts, cost breakdowns, rights and commitments) are not shown here.
Timeline · acts, filings and financial milestones
Next filing, fiscal year 2026, expected by
2026
10-02
NBB filing
Annual accounts filed
fiscal year 2025 · micro schema
2025
31-12
Financial
Back to profitnet €15k
Net result €15k after 2 loss-making years.
13-08
NBB filing
Annual accounts filed
fiscal year 2024 · micro schema · 13 days late
2024
27-08
NBB filing
Annual accounts filed
fiscal year 2023 · micro schema · 27 days late
2023
31-12
Financial
Weakest financial yearnet €-3k ▼1755%
Net result drops to €-3k, the lowest in the series; recovery starts the following year.
28-08
NBB filing
Annual accounts filed
fiscal year 2022 · micro schema · 28 days late
2022
19-08
NBB filing
Annual accounts filed
fiscal year 2021 · micro schema · 19 days late
2021
25-08
NBB filing
Annual accounts filed
fiscal year 2020 · micro schema · 25 days late
Financial milestoneNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.
Directors · office · real estate
Directors
1 act for this company is in the Belgian State Gazette, of which we have read 0. We have therefore not extracted its directors from those acts yet.
Location & real-estate footprint
Registered office, Ranst · 1 establishment unit since 2020
Cannot be placed on the map
This address could not be matched to a point in the Belgian address register (BOSA BEST). The address below comes straight from the Crossroads Bank.
Korenveld 272520 RanstGround area
596 m²
Building footprint
148 m²
Volume, LiDAR
824 m³
Parcel 11035C0185/00W006, Flanders · tallest building 8.9 m, ±2 floors. Linked by address, not a title deed.
1 establishment unit
Farmaco
since 20202.301.376.468
1 parcel
Flanders
1
(100%)
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 11035C0185/00W006 | Flanders | 596 m² | 1 · 148 m² | 8.9 m · 2 fl. |
Linked by address, not proof of ownership
Methodology
via registered seat: 1
1 of 1 parcel with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.
Similar companies · same sector, comparable size
APOTHEEK VERSCHAEVE-BARTELEN
BE 0451.903.303
Beveren-Kruibeke-Zwijndrecht · Eq €1k
LISANNE MOONS
BE 0737.837.230
Zonhoven · Eq €1k
AVERROES PHARMA
BE 0738.813.960
Sint-Jans-Molenbeek · Eq €999
APOTHEEK VERSE
BE 0893.942.595
Brussel · Eq €912
MDN Pharmaceutics
BE 1032.175.218
Brussel · Eq €873
Of 5,224 companies in sector 47730 we hold annual accounts for 3,864. 87 are within a factor 10 of this equity.See the whole sector
Company data · Crossroads Bank
Identification
Legal formPrivate limited company
Founded17-04-2020
Fiscal year end31-12
Activities, NACEBEL
47730Retail sale of pharmaceutical products
Sources
Crossroads Bank for EnterprisesNational Bank · 6 filingsAddress and cadastre registers
Data from official sources, last processed on 16-09-2026. Scores and ratios are computed by Checked and are not a credit decision.